Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.
Pizzutilo EG, Agostara AG, Roazzi L, Romanò R, Motta V, Lauricella C, Marrapese G, Cerea G, Signorelli D, Veronese SM, Giannetta LG, Sartore-Bianchi A, Siena S. Pizzutilo EG, et al. Among authors: siena s. JTO Clin Res Rep. 2023 Jul 26;4(11):100555. doi: 10.1016/j.jtocrr.2023.100555. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 38047274 Free PMC article.
Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea.
Mauri G, Pedrani M, Ghezzi S, Bencardino K, Mariano S, Bonazzina E, Serra F, Pedrazzoli P, Caccialanza R, Cavestro GM, Siena S, Artale S, Sartore-Bianchi A. Mauri G, et al. Among authors: siena s. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e885-e889. doi: 10.1136/spcare-2023-004203. BMJ Support Palliat Care. 2024. PMID: 37344158 Free PMC article.
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Sogari A, Rovera E, Grasso G, Mariella E, Reilly NM, Lamba S, Mauri G, Durinikova E, Vitiello PP, Lorenzato A, Avolio M, Piumatti E, Bonoldi E, Aquilano MC, Arena S, Sartore-Bianchi A, Siena S, Trusolino L, Donalisio M, Russo M, Di Nicolantonio F, Lembo D, Bardelli A. Sogari A, et al. Among authors: siena s. Cell Rep Med. 2024 Feb 20;5(2):101376. doi: 10.1016/j.xcrm.2023.101376. Epub 2024 Jan 15. Cell Rep Med. 2024. PMID: 38228147 Free PMC article.
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers.
Mauri G, Patelli G, Roazzi L, Valtorta E, Amatu A, Marrapese G, Bonazzina E, Tosi F, Bencardino K, Ciarlo G, Mariella E, Marsoni S, Bardelli A, Bonoldi E, Sartore-Bianchi A, Siena S. Mauri G, et al. Among authors: siena s. J Clin Pathol. 2024 Feb 13:jcp-2023-209341. doi: 10.1136/jcp-2023-209341. Online ahead of print. J Clin Pathol. 2024. PMID: 38350716 Free article.
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.
Roazzi L, Patelli G, Bencardino KB, Amatu A, Bonazzina E, Tosi F, Amoruso B, Bombelli A, Mariano S, Stabile S, Porta C, Siena S, Sartore-Bianchi A. Roazzi L, et al. Among authors: siena s. Clin Colorectal Cancer. 2024 Feb 16:S1533-0028(24)00006-9. doi: 10.1016/j.clcc.2024.02.001. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 38519391 Review.
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Fan Y, Drilon A, Chiu CH, Loong HHF, Siena S, Krzakowski M, Dziadziuszko R, Zeuner H, Xue C, Krebs MG. Fan Y, et al. Among authors: siena s. Clin Lung Cancer. 2024 Mar;25(2):e81-e86.e4. doi: 10.1016/j.cllc.2023.12.001. Epub 2023 Dec 7. Clin Lung Cancer. 2024. PMID: 38245456 Free article. No abstract available.
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Van Cutsem E, Yaeger R, Delord JP, Tabernero J, Siu LL, Ducreux M, Siena S, Elez E, Kasper S, Zander T, Steeghs N, Murphy D, Edwards M, Wainberg ZA. Van Cutsem E, et al. Among authors: siena s. Oncologist. 2023 Dec 11;28(12):e1209-e1218. doi: 10.1093/oncolo/oyad210. Oncologist. 2023. PMID: 37597246 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Van Cutsem E, et al. Among authors: siena s. Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14. Lancet Oncol. 2023. PMID: 37329891 Clinical Trial.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Strickler JH, et al. Among authors: siena s. Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. Lancet Oncol. 2023. PMID: 37142372 Clinical Trial.
436 results